Creso Pharma Limited (ASX:CPH) brings its pharmaceutical skills and knowledge to the cannabis sector and strives for the highest quality in its products. The Company’s cannabis and hemp-derived products include therapeutic, nutraceutical, as well as lifestyle products.
Creso is providing pharmaceutical expertise with the delivery of the highest quality cannabis-based products. In this context, therapeutic-grade nutraceuticals derived from hemp are additional products the cannabis firm has been working on.
The Company uses Good Manufacturing Practice (GMP) standards to develop and manufacture its products with initial product registrations in Switzerland. The Company has global rights for several unique and proprietary pioneering delivery technologies that improve the bioavailability and absorption of cannabinoids.
Source: CPH Website
The group focuses on expanding its presence in the international markets and aims to offer a diverse product portfolio worldwide. The products developed by Creso are categorised into four categories - therapeutics, animal health, nutraceuticals, topicals and lifestyle.
Creso Pharma’s products are based on cannabis and hemp grown with the GAP (Good Agricultural Practices) while being manufactured as per the highest quality standards by using GMP facilities where appropriate.
With the proposed acquisition of Canada-based Halucenex Inc., Creso Pharma is all set to enter the psychedelic space and will become the first ASX-listed wholly-owned psychedelic medicines company.